Summary Tc-99m 2 methoxy-isobutyl-isonitrile (9SmTc-MIBI), also called Sestamibi, is a safe and effective scanning agent in solid tumours. Its use in imaging lesions in multiple myeloma has been studied in 21 patients with either multiple myeloma (19/21) or monoclonal gammopathy of undetermined significance (MGUS) (2/ 21). 99mTc-MIBI scanning was positive in 14 patients, 13 with active myeloma and one patient with MGUS showing possible transformation to a more accelerated phase. In seven patients 99mTc-MIBI scanning was negative. In four of them, the result was unexpected, as they had the features of active myeloma. All four were either primarily or secondarily resistant to chemotherapy, with high total cumulative doses of doxorubicin. Overexpression of P-glycoprotein associated with multidrug resistance could be a factor, as it has been shown that 99'Tc-MIBI is actively eliminated from the cell by P-glycoprotein. With this assumption, sensitivity of the scanning technique in this series is 100%, and the specificity 88%. No A dose of 450 MBq of 99mTc-MIBI was administered to each patient. After reviewing 10 min, 1, 4 and 24 h planar images, those done at 1 and 4 h after injection were obtained and evaluated in each patient. A Siemens Orbiter 75 gamma camera equipped with a low-energy, general purpose parallelhole collimator linked to a Micas V computer (Park Medical) was used. Pulse height analysis was carried out with a 15% window on the peak energy of 140 keV for 99mTc-MIBI. A posterior view of the pelvis was done for 600 000counts; the other spot views, anteriorly and posteriorly of the body, were acquired with the same preset time. Physiological uptake of 99mTc-MIBI was seen in the heart, thyroid and salivary glands, spleen, kidneys, bladder, lungs, skeletal muscle, liver, gall bladder, biliary system and both small and large intestines.
Technetium-99m 2 methoxy-isobutyl-isonitrile (99mTc-MIBI) is a tracer with gamma emission characteristics that was introduced in 1984 as an alternative to TI-201 for the study of myocardial perfusion. The agent gave satisfactory results and was well tolerated (Wackers et al., 1989) . Clinical observations and laboratory information on the mechanism of uptake of 99mTc-MIBI led to new proposals for its use in cancer patients.
In 1987, uptake of 99mTc-MIBI by pulmonary metastases of thyroid cancer was described by Muller et al. (1987) ; since then, it has been studied in bronchial carcinomas (Muller et al., 1989) , osteosarcomas (Hassan et al., 1989 ), brain tumours (Albuquerque et al., 1992) , tumours of the nasopharynx (Kao et al., 1993) , breast cancer (Khalkhali et al., 1994) , parathyroid adenomas (Coakley et al., 1989) and lymphomas (Kostakoglu et al., 1992) .
In 1994, Durie et al. first showed the increased uptake of 99mTc-MIBI by bone lesions in patients with active multiple myeloma (MM). Those preliminary data were encouraging, and were confirmed by Malpas et al. and Unlu et al. in 1995. A potential advantage of 9'Tc-MIBI scan in predicting multidrug resistance (MDR) has been suggested by some authors (Ballinger et al., 1995) , since there is both in vivo and in vitro evidence that P-glycoprotein (which has been associated with MDR) is responsible for the elimination of MIBI from several types of malignant cells. There have been no clinical studies in myeloma patients to verify the assumption.
The role of 99mTc-MIBI in the detection of MM in bone marrow has been examined with regard to reliability, sensitivity and toxicity, and compared with radiography as the standard reliable imaging technique. Figure 2 Active myeloma (patient PJ). 99mTc-MIBI images of the posterior thoracic spine. Extensive bone marrow uptake in the thoracic vertebrae, all the ribs and scapulae is seen, so that the image almost looks like a bone scan. Normal uptake is seen in the heart, liver, spleen and gut inferiorly. The 14 patients with positive results were examined to see how effective 99mTc-MIBI scanning was in detecting active disease in bones, and whether clinical, biochemical and radiological information corresponded with 99mTc-MIBI scanning.
Twelve of the 14 patients with increased uptake had active myeloma confirmed both clinically and biochemically; one was deemed to have indolent MM with an increased 'M' band and bone marrow involvement, but no symptomatology, and a negative skeletal survey. There was enough evidence to suggest that the patients studied had bone marrow involvement, and therefore the results of the 99mTc-MIBI scan in these 13 cases (93%) were characterised as true positive (TP) ( Table I) .
Skeletal survey or MRI scanning indicated bony involvement in 11/14 patients (78%) who had positive 99mTc-MIBI scans. All these patients were diagnosed as having active disease; three of them were newly diagnosed and therefore previously untreated (Tables I and II) . The results of 99mTc-MIBI scanning relating to the localisation of bone lesions were almost or completely concordant with those of skeletal survey in 6/11 (54%) patients. There was, however, partial concordance in the results of the remaining five (Table II, Figure 5a and b).
The 99mTc-MIBI scan was positive in one patient with MGUS (1/14; 7%). This has to be considered as a falsepositive result (Table I ). The results of the 7/21 (33%) patients in whom 99mTc-MIBI scanning was negative (6/7) or showed transient uptake at 1 h (1/7) included four (60%) false negatives (FN) ( Table  I) . One of these patients (IF) had a history of primary resistance to therapy, and the other three had received large cumulative doses of anthracycline, which could have contributed to their multidrug resistance (MDR) (Table III) and would be likely, therefore, to cause a negative 99mTc-MIBI scan.
In the 3/7 (43%) cases with negative 99mTc-MIBI scans, the results were as expected (true negatives), since one patient was diagnosed as having MGUS and the remaining two patients were in remission ( Table I) .
The sensitivity and specificity of 99mTc-MIBI scanning in MM patients, estimated according to the above results, were found to be 82% and 75% respectively. These figures would significantly increase (the sensitivity to 100% and the specificity to 88%) if the negative results from the MDR cases were considered as true.
Discussion
Various bone-seeking radiopharmaceutical agents have been used in multiple myeloma, the commonest being technetium99m methylene diphosphate (Wahner et al., 1980) . It has been shown that conventional radionuclide bone imaging is less sensitive at detecting skeletal lesions than conventional radiography. Conventional radiography will detect individual lesions in 75-95% of cases, while the equivalent sensitivities for radionuclide bone imaging range from 40% to 60% (Feggi et al., 1988) . Myeloma generally produces a poor osteoblastic response and, therefore, radiopharmaceutical agents, such as technetium-99m-labelled diphosphonate, are poorly taken up.
At present, the most reliable method of detecting bone disease in MM is radiography, with about 80% sensitivity (Waxman et al., 1981) . However, the lesions shown on the radiographic films do not always signify active disease, but may represent lesions already healed. In addition, radiography is not able to detect areas of disease in the bone marrow.
In this pilot study, 99mTc-MIBI has produced results comparable with radiography. Images at 10 min showed high blood pool activity. Uptake of MIBI was clearly seen at 1 h and contrast increased at 4 h. Fading of uptake at 24 h was noted in some patients. 99mTc-MIBI is well tolerated and does not have any toxic effects. There is good concordance between the findings of the 99'Tc-MIBI scan and the skeletal survey in those patients with active disease. There are some patients with partially concordant results (Table II) , Where lesions shown on skeletal survey do not always correspond to the positive areas of the 99mTc-MIBI scan, and vice versa. The mechanism of uptake of 99mTc-MIBI could help to explain these results.
The main mechanism of cellular uptake of 99mTc-MIBI has been shown to involve passive distribution across the plasma cell and mitochondrial membranes in tissues that maintain negative plasma membrane potentials or are rich in mitochondrial content, i.e. myocardial, renal or hepatic cells (Piwnica-Worms et al., 1990) . However, alterations in cell metabolism, which occur in malignant cells, can affect the membrane potential, which can then influence the accumulation of "mTc-MIBI within the cell (Chen, 1988 radiography is unable to reveal abnormalities of constituents of the marrow. Furthermore, healed lesions which might appear on the radiographic films or MRI scans of previously treated patients do not show increased uptake on 99mTc-MIBI scanning (Figure 5a and b) . It is, however, interesting that there are abnormal areas on skeletal survey that do not appear positive on 99mTc-MIBI scanning in previously untreated patients. These may represent areas of drug resistance, since there is both in vivo and in vitro evidence that P-glycoprotein (which is associated with drug resistance in MM) is responsible for the elimination of 99mTc-MIBI from malignant cells (Ballinger et al., 1995) .
The potential application of 99mTc-MIBI scanning in the functional detection of drug resistance, either before chemotherapy in various tumours known to be primarily resistant, or during chemotherapy to monitor acquired drug resistance has been explored (Moretti et al., 1995a, b) . It has been shown that 99'Tc-MIBI is a transport substrate recognised by the human MDR1 P-glycoprotein (P-gp), which recognises and transports out of the cell a large group of cytotoxic compounds having little or no structural or functional similarities other than being relatively small, hydrophobic and cationic (i.e. anthracyclines) (Pearce et al., 1989) . 99mTc-MIBI also fulfils these requirements. In vitro studies have confirmed that it can be transported by P-gp (Piwnica-Worms et al., 1993) . It has also been immunohistochemically confirmed that P-gp expression is associated with MDR in myeloma cells (Dalton et al., 1989) . The four cases in our study in which 9"Tc-MIBI scanning was negative or showed slightly increased uptake only at 1 h after injection, despite the activity of the disease, could be explained by 99mTc-MIBI elimination of myeloma cells as a result of MDRl P-gp overexpression, since the clinical histories indicated either primary or acquired drug resistance. Immunohistochemical detection and quantitation of P-gp in suspicious areas showing no uptake of 99mTc-MIBI would help to confirm the overexpression of P-gp and its relation to 99mTc-MIBI negativity, and these studies are in progress.
If the drug-resistant cases are accepted as true-negative results, then the sensitivity and specificity of 99mTc-MIBI scanning increase considerably, from 82% to 100%, and from 75% to 88% respectively.
The unexpected positive scan in one patient with MGUS raises the question whether 99mTc-MIBI scanning could detect progression of MGUS to MM earlier than any other imaging procedure; this is a matter for further research.
In conclusion, this pilot study shows that 99mTc-MIBI scanning is a useful addition to the investigation process for MM, and in the management of patients with plasma cell disorders.
